Cambridge University Press
  • Welcome Guest user
  • Log in | Register
 
Athens log in
Username Password  
Forgot your password?
Subscribe now to view full content , or if you already have an account,
please Login to access this feature
Subscribe now to view full content, or if you already have an account,
please Login to access this feature
Subscribe now to access this feature, or if you already have an account,
please Login.
 
 
  • Advanced search
Cambridge University Press logo
Stahl's Essential Psychopharmacology Online
In Collaboration With NEI
Stahl's Essential Psychopharmacology

Navigation

  • Home
  • The
    Prescriber's Guide
  • Essential
    Psychopharmacology
  • Essential
    Neuropharmacology
  • Other
    Resources
    • Next Generation Antidepressants:
      Beyer and Stahl
  • Stahl's
    Illustrated
  • Drug
    Interaction
 
  • My Bookmarks
  • TOC
  • Rivastigmine
  • Therapeutics
  • Side Effects
  • Dosing and Use
  • Special Populations
  • Art of Psychopharmacology
  • Suggested Reading

Rivastigmine

Therapeutics

Brands

• Exelon, Prometax

Generic?

No

Class

• Cholinesterase inhibitor

Commonly Prescribed for

(FDA approved in bold)
• Alzheimer dementia (AD) (mild or moderate)
• Dementia associated with Parkinson's Disease (PD)
• Dementia with Lewy Bodies (DLB)
• Vascular dementia

How the Drug Works

• Increases the concentration of acetylcholine through reversible inhibition of acetylcholinesterase, which increases availability of acetylcholine. Also inhibits butyrylcholinesterase. A deficiency of cholinergic function is felt to be important in producing the signs and symptoms of AD. May interfere with amyloid deposition
• Although symptoms of AD can improve, rivastigmine does not prevent disease progression

How Long Until It Works

• Typically 2-6 weeks at a given dose, but effect is best observed over a period of months

If It Works

• Continue to use but symptoms of dementia usually continue to worsen

If It Doesn't Work

• Non-pharmacologic measures are the basis of dementia treatment. Maintain regular schedules and routines. Avoid prolonged travel, unnecessary medical procedures or emergency room visits, crowds, and large social gatherings
• Limit drugs with sedative properties such as opioids, hypnotics, antiepileptic drugs and tricyclic antidepressants
• Treat other disorders which can worsen symptoms such as hyperglycemia or urinary difficulties

Best Augmenting Combos for Partial Response or Treatment-Resistance

• Addition of the NMDA receptor antagonist memantine may be beneficial
• Treat depression or apathy, if present, with SSRIs. Avoid tricyclic antidepressants in demented patients due to risk of confusion
• For significant confusion and agitation avoid typical neuroleptics (especially in DLB) because of the risk of neuroleptic malignant syndrome. Atypical antipsychotics (risperidone, quetiapine, olanzapine, clozapine) can be used instead

Tests

• None required
 

Current Prices for Individual Subscribers (prices are subject to change)

  Pay-per-view Subscription (48 hours) Unit price

Subscribe

Stahl's Essential Psychopharmacology Online

Revised and Updated Edition 3rd Edition

ISBN: 9780511447990


$ 40
  Annual Subscription (Single User) Unit price

Subscribe

Stahl's Essential Psychopharmacology Online

Revised and Updated Edition 3rd Edition

ISBN: 9780511447983


$ 195
  Print + Online Access (One Year, Single User) Unit price

Purchase

Stahl's Essential Psychopharmacology Online

Digital Edition: Print and Online

Once you are sent the Digital Edition, just enter the code from the inside back cover to activate your one-year access to www.stahlonline.org.

ISBN: 9780521746090


$261
For pricing and information for Academic and Medical Libraries, Corporate, Nonprofit or Government Institutions and/or special sales or website sponsorship,

for the Americas please contact:
Cambridge Library Sales,
stahlonline@cambridge.org,
800-221-4512, x6535.

For the rest of the world, please contact:
academicsales@cambridge.org
or call +44 (0) 1223 325741.

Australia and New Zealand
Phone: +61 (3) 8671 1400,
Fax: +61 3 9676 9966,
Email: enquiries@cambridge.edu.au.

 

Footer links

  • About Cambridge University Press
  • About NEI
  • About Dr. Stahl
  • About the Illustrator
  • © Cambridge University Press 2008.
  • Copyright statement
  • Privacy Policy
  • Accessibility
  • Terms of use
  • FAQ
  • Help
  • View Access Details
  • Contact us